From Wikipedia, the free encyclopedia
Monoclonal antibody
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[2]
|
|---|
| Angiopoietin | |
|---|
| CNTF | |
|---|
| EGF (ErbB) | |
|---|
| FGF | | FGFR1 | |
|---|
| FGFR2 |
- Agonists: Ersofermin
- FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)
- Palifermin
- Repifermin
- Selpercatinib
- Sprifermin
- Trafermin
|
|---|
| FGFR3 | |
|---|
| FGFR4 | |
|---|
| Unsorted | |
|---|
|
|---|
| HGF (c-Met) | |
|---|
| IGF | |
|---|
| LNGF (p75NTR) | |
|---|
| PDGF | |
|---|
| RET (GFL) | |
|---|
| SCF (c-Kit) | |
|---|
| TGFβ | |
|---|
| Trk | | TrkA |
- Negative allosteric modulators: VM-902A
|
|---|
| TrkB |
- Agonists: 3,7-DHF
- 3,7,8,2'-THF
- 4'-DMA-7,8-DHF
- 7,3'-DHF
- 7,8-DHF
- 7,8,2'-THF
- 7,8,3'-THF
- Amitriptyline
- BDNF
- BNN-20
- Deoxygedunin
- Deprenyl
- Diosmetin
- DMAQ-B1
- HIOC
- LM22A-4
- N-Acetylserotonin
- NT-3
- NT-4
- Norwogonin (5,7,8-THF)
- R7
- R13
- TDP6
|
|---|
| TrkC | |
|---|
|
|---|
| VEGF | |
|---|
| Others |
- Additional growth factors: Adrenomedullin
- Colony-stimulating factors (see here instead)
- Connective tissue growth factor (CTGF)
- Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
- Erythropoietin (see here instead)
- Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
- Glia maturation factor (GMF)
- Hepatoma-derived growth factor (HDGF)
- Interleukins/T-cell growth factors (see here instead)
- Leukemia inhibitory factor (LIF)
- Macrophage-stimulating protein (MSP; HLP, HGFLP)
- Midkine (NEGF2)
- Migration-stimulating factor (MSF; PRG4)
- Oncomodulin
- Pituitary adenylate cyclase-activating peptide (PACAP)
- Pleiotrophin
- Renalase
- Thrombopoietin (see here instead)
- Wnt signaling proteins
- Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)
|
|---|
N
Y (what is this?) (verify)
